Study Subject Enrollment Sample Clauses

Study Subject Enrollment. Provider 2.
Sample 1
AutoNDA by SimpleDocs
Study Subject Enrollment. Institution and/or Investigator shall use its reasonable good 2. Zařazování subjektů do studie. Zdravotnické zařízení a/nebo zkoušející vyvinou faith efforts to enroll Study Subjects who meet the requirements of the Protocol or as otherwise set forth in the written instructions provided by the Sponsor. After the fourth th) Study Subject is randomized to the Study at the Institution, Institution or Investigator must seek Sponsor approval prior to initiating additional screening activities to enroll more Study Subjects after the th Study Subject. Sponsor approval must be documented in writing via email or other written approval. Payments for all Subjects enrolled by Institution with Sponsor written approval, are subject to the terms of this Agreement, payment terms and the Study Budget. v dobré víře přiměřené úsilí a zařadí do studie subjekty, které splňují požadavky protokolu nebo jiné požadavky uvedené v písemných pokynech zadavatele. Poté, co dojde k randomizaci čtvrtého subjektu studie ve zdravotnickém zařízení, musí zdravotnické zařízení nebo zkoušející získat souhlas zadavatele xxxxxxx, xxx xxxxxx xxxxxxxxx screening pro zařazení dalších subjektů studie po subjektu studie. Souhlas zadavatele musí být doložen písemně ve formě e-mailu nebo jiného písemného souhlasu. Platby pro všechny subjekty studie zařazené zdravotnickým zařízením s písemným souhlasem zadavatele podléhají podmínkám této smlouvy, platebním podmínkám a rozpočtu studie.
Sample 1
Study Subject Enrollment. Institution has agreed that Principal Investigator will enroll Study Subjects in the Study in accordance with the Protocol and in accordance with IEC and/or RA approval. Sponsor may discontinue Study Subject enrollment if the total enrollment needed for a multi-center Study has been achieved, if applicable. 7.
Sample 1
Study Subject Enrollment. Upon receipt of any notice of termination or suspension, University and Principal Investigator agree that no additional Study subjects will be enrolled in the Study. Any Study subjects already enrolled in the Study will be phased-out as deemed appropriate by Company and Principal Investigator. Company shall give University a minimum of fourteen (14) days notice before closing enrollment so University does not incur unnecessary costs or disappoint potential Subjects that are in the recruiting process.
Sample 1
Study Subject Enrollment hodnocení dodají Instituci dostatečná množství Hodnoceného přípravku k provádění Klinického hodnocení dle podmínek v Protokolu.
Sample 1
Study Subject Enrollment. Institution agrees to enroll qualified Study Subjects in the Study, in accordance with the Protocol and in accordance with IEC and/or RA approval. A qualified Study Subject is one whom meets all the Protocol criteria for participation in the Study. Principal Investigator announces the inclusion of the Study Subject to the Study specifying the decision number of the Study and the date of inclusion of the Study Subject in the Study to the health insurance company conducting the Public Health Insurance of Study Subject immediately after inclusion of the Study Subject to the Study in accordance with the provisions of Section 26 of No. 576/2004 Coll.. Sponsor may discontinue Study Subject enrollment if the total enrollment needed for a multi-center Study has been achieved or before Institution has enrolled the minimum number of Study Subjects. Protocol does not require hospitalization during the course of the Study. 6.
Sample 1
Study Subject Enrollment. Institution has agreed to enroll Study Subjects in the Study in accordance with the Protocol and in accordance with IEC and Competent Authority approvals. Sponsor may discontinue Study Subject enrollment if the total enrollment needed for a multi-center Study has been achieved, if applicable. Protocol does not require hospitalization during the course of the Study. Informed Consent. Institution shall ensure that the Informed Consent Form (“ICF”), which must comply with Applicable Law, as approved by Sponsor, Sponsor’s Designee (Syneos Health), the IEC and, if required, the Competent Authority, is properly executed by each Study Subject before (i) such Study Subject is enrolled in the Study; and (ii) any personal data of such Study Subject is processed. 7.
Sample 1
AutoNDA by SimpleDocs
Study Subject Enrollment. Institution and/or Investigator shall use its reasonable good faith efforts to enroll Study Subjects who meet the requirements of the Protocol or as otherwise set forth in the written instructions provided by the Sponsor. After the fourth (4th) Study Subject is randomized to the Study at the Institution, Institution or Investigator must seek Sponsor approval prior to initiating additional screening activities to enroll more Study Subjects after the 4th Study Subject. Sponsor approval must be documented in writing via email or other written approval. Payments for all Subjects enrolled by Institution with sponsor written approval are subject to the terms of this Agreement, payment terms and the Study Budget. 2.
Sample 1

Related to Study Subject Enrollment

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Completion of Review for Certain Review Receivables Following the delivery of the list of the Review Receivables and before the delivery of the Review Report by the Asset Representations Reviewer, the Servicer may notify the Asset Representations Reviewer if a Review Receivable is paid in full by the Obligor or purchased from the Issuer in accordance with the terms of the Basic Documents. On receipt of such notice, the Asset Representations Reviewer will immediately terminate all Tests of the related Review Receivable, and the Review of such Review Receivables will be considered complete (a “Test Complete”). In this case, the related Review Report will indicate a Test Complete for such Review Receivable and the related reason.

  • Tests 7.7.1 If the Contract Documents, laws, ordinances, rules, regulations or orders of any public authority having jurisdiction require any portion of the Work to be inspected, tested or approved, the Contractor shall give the Architect timely notice of its readiness so the Architect may observe such inspection, testing or approval. The Contractor shall bear all costs of such inspections, tests or approvals conducted by public authorities.

Time is Money Join Law Insider Premium to draft better contracts faster.